Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That's because CNS distribution with sd-rxRNA can penetrate the cells.
Rxi currently has macular degeneration, scarring, etc.
With CNS drug Rxi could target
Spinal muscular Atrophy -- SMA which Isis is partnered with Biogen on etc. and many other possiblities in CNS.
Shorts Will be out of RXII soon look at all the new institutional holdings.
http://relationalstocks.com/stockquote.php?op=instholding&tickersymbol=RXII
Plus today's volume smells of a new 13G filing after the bell today IMO.
They will try but right now its rough for those short sellers because
1.) For one their is a lot of buying going on everyday they are having a hard time shorting
2.) Chart looks amazing and the stock has been up the last 4 to 5 days. When day traders see this they attempt to jump in on the action
3.) Back to #1 if the short sellers can't keep share price down they are forced to cover at higher prices.
Either way tomorrow should be an exciting day for RXII
RXII closed HOD this is coiled to go higher. Plus 3.5 mil short volume should add the fuel to the fire to go even higher. Gap up tomorrow is possible!
No clue but CEO Dr. Geert C. just bought another 35,000 shares of RXII yesterday June 22, 2015. It was filed just this morning seen here http://investors.rxipharma.com/ShowFile.aspx?KeyFile=30056028&Format=XML&Output=XML
IND for RXI-109 in retinal scarring of macular degeneration should get this moving. Plus any other new scar trial results and partnerships!
Hopefully we hear something about the neurodegenerative deal in the Central Nervous System Space.
good for you. I mean the new patents they just released is a hint. If you look at the press release you can see one new positive item and one hint on deal.
for instance read this:
Importantly, this patent expands the scope of RXi's self-delivering RNAi platform with the incorporation of novel oligonucleotide chemical modifications. These chemical modifications result in improved biodistribution following systemic administration and may be beneficial for local delivery applications in the central nervous system.
1.) if you look at the first part it says the systemic delivery is improved
2.) if you look at second part it says patent for CNS -- Central nervous system -- that's a hint that the nuerodegernative deal is close -- CNS =- neurodegenerative
Short term its being beaten down by day traders and short sellers. About 3.5 mil short volume last I checked. Anyways I'm averaging down more shares for Monday.
I think the upcoming IND for retinal scarring macular degeneration will put a huge spotlight on RXII. As there are no drugs approved for scarring and no drugs approved for scarring of macular degeneration.
I will continue to hold long-term because I know that this company will not be trading where its at one year from now when we see the new early results in hypertrophic scars and keloids.
This is not just patent news read this
" Importantly, this patent expands the scope of RXi's self-delivering RNAi platform with the incorporation of novel oligonucleotide chemical modifications. These chemical modifications result in improved biodistribution following systemic administration and may be beneficial for local delivery applications in the central nervous system."
That means Rxi just improved its sd-rxRNA technology platform for systemic diseases with chemical modifications. Also improved local delivery for Central nervous system diseases.
Yep more news
http://finance.yahoo.com/news/rxi-pharmaceuticals-strengthens-intellectual-property-110200033.html
Those patents are huge they are for Central Nervous System diseases, inflammatory diseases and metabolic diseases.
Retinal Scarring of macular degeneration IND is approaching mid 2015
Also if the CEO closes that Neurodegenerative deal with that pharma company he was talking about. CEO stated that the deal would be similar to MirImmune deal.
Plus early results in hypertrophic scars and keloids coming up as well.
Plenty of catalysts to raise share price.
The outstanding shares now is about 50 to 60 mil and depending upon whether future warrants are exercised as well.
But you are correct in that RXII ownership is up around 42% and 46% including previous institutions though.
In addition I don't think this is the last of a large stake that is taken for RXII. As more institutions get wind of RXII working on a scarring drug more will buy shares for two reasons:
1.) Early results show that RXI-109 works better than placebo
2.) There are "Zero" FDA approved drugs for scarring meaning that Rxi has the potential to be the first company ever approved for scarring.
Lets see
Tang Capital 7.42%
Sabby Healthcare 6%
Frigate Venture LP 7%
Empery Asset Management 7%
Intracoastal LLC 5%
Opko Health 7%
Broadfin Capital 5.44%
Vanguard group 1.5%
If we add all that up that should be about 46% ownership. I added Opko Health even though it's not an institution but it still owns 7.44% of RXII shares.
That's a lot of ownership of 46% and I'm sure their will be more filings soon as well. Good luck to all.
Especially with this. Intercoastal LLC bought 3.4 million shares RXII 5% ownership as well. Make that the 4th institution that has bought shares in the last week and a half.
http://investors.rxipharma.com/Cache/c29885220.html
More Press Coverage for RXII
The Rising Tide in Larger Markets Spurs New Interest In Small-Cap Stocks
http://finance.yahoo.com/news/rising-tide-larger-markets-spurs-112000646.html
Rxi continues to get recognition over and over again. It will turn around and the turn around will be dramatically fast.
http://www.wsobserver.com/fall-in-love-with-these-4-biotech-stocks-rxi-pharmaceuticals-nasdaqrxii-agenus-nasdaqagen-immunomedics-nasdaqimmu-juno-therapeutics-nasdaqjuno/7217789/
I don't know if many of you are not paying attention or didn't notice but read this line on slide #29 from the Jefferies Presentation
" Extension study for Hypertrophic scars (Severe Cases)"
If RXI-109 wasn't working why would Rxi expand upon a new expansion study for more severe cases of hypertrophic scars? This leads me to believe the new added dosing is working even better. As the company would not target more severe cases of hypertrophic scars if the drug wasn't working in less severe cases of hypertrophic scars
When they said institutions I thought maybe one Empery Asset Management. Then we get Frigate Ventures LP and Sabby Healthcare Management. Sabby is huge they buy the best biotechs-- they don't buy unless they do some serious DD.
I'm sure there's plenty of more institutions to come. But these institutions have been in already plus the new ones we got this week
Tang owns 7.44% unless he sold -- we shall see
Opko Health owns about 7.44%
Broadfin Capital owns 5.44%
Sabby bought 2.3 million shares RXII I guess translates to 3 or 4%
Frigate Venture bought 7%
Empery Asset management bought 7%
Rxi Highlights from Presentation -- Jefferies
1. Similar deal like MirImmune is being negotiated upon with another company in the neurodegenerative space. This could be brought out in the next month or 2 months.
2. IND for RXI-109 is close for mid 2015
3. Preferred shareholder is gone no more preffered shares
4. Early results for hypertrophic scars 1402 and early results for Keloids study 1401 will be shown soon
5. Cash on hand with all warrants exercised will last company till Q3 2017
Dr. Geert C will be presenting today at the 2015 Jefferies Global Healthcare Conference
The presentation will be webcast live at 11:30 a.m. EST time don't miss it!
Leave him be if the tech works this will be way higher, but that's the way the stock market works. Those who are patient win! The others well... they just lose.
what are you talking about. Those .52 are warrants that doesn't cap the stock you sir are nuts.
New SEC filings. All management and directors bought Option shares set to expire in June 2025
http://investors.rxipharma.com/insiders.aspx?IID=4418218
Yep pretty much means they bought 7.85% stake and offering was 26 million shares although there could possibly be more SEC filings coming on the way. That we don't know
WoW today is awesome first RXI on CBC documentary channel on Jun 8th for the whole week and now more news:
Empery Asset Management, LP just filed a "Statement of acquisition of beneficial ownership", which is also known as a 13G. In the filing, it appears as though Empery Asset Management, LP claims to own 4,500,000 shares. This represents 7.86% of RXi Pharmaceuticals
Volume surge RXII probably for this reason
According to big guy on stocktwits
"RXi Pharmacueticals will be featured on CBC's Documentary Channel beginning Jun 8, 2015, Monday through Friday"
Say goodbye to these levels
Info on Business Television:
Shot on location, BTV takes INVESTORS directly to companies!
BTV-Business Television, a half-hour weekly business TV program features emerging companies and top industry analysts across the US and Canada broadcast to over 100 million households on FOX Business News, BNN, America One Biz Network and American Business Network.
Even Better New Video on Business Television for RXII
http://www.b-tv.com/rxi-pharma-ceo-clip/
RXi Pharmaceuticals' CEO Dr. Geert Cauwenbergh Interviewed by The Life Sciences Report
http://finance.yahoo.com/news/rxi-pharmaceuticals-ceo-dr-geert-110200565.html
New Seeking Alpha Article for Vertex
"Vertex Pharmaceuticals Takes Another Step Forward For Cystic Fibrosis Patients"
http://seekingalpha.com/article/3221326-vertex-pharmaceuticals-takes-another-step-forward-for-cystic-fibrosis-patients
Look if this was just a dilution purely on the public only I would be worried. It will add more RXII shares to the float as many have pointed out many times. But why is nobody looking at the positive?
"We will enter into securities purchase agreements directly with certain institutional investors which will purchase not less than $100,000 of units in this offering. We will not enter into any securities purchase agreement with investors which will purchase less than $100,000 of units in this offering and such investors which purchase less than $100,000 shall rely solely on this prospectus in connection with the purchase of securities in this offering. The Placement Agent may retain one or more sub-agents or selected dealers in connection with the offering."
That says it all these big institutions are buying huge stakes of RXII that establishes a few things:
1. Big institutions hold shares long term that means all 25 mil shares just released will be held long term
2. After the offering it is more likely than not we will see who the big institutions are that bought shares, and if they are big that itself will move the share price higher depending who they are.
3. Money problem is now solved for two years till the end of 2017 and Tang Capital has converted all preferred shares that mean a rebound is in order.
4. We have the IND filing for retinal scarring of macular degeneration mid 2015. That should take place by June/July 2015
5. Other pre-clinical programs are ongoing we may see pre-clinical results in macular degeneration, Tyrosinase, and collagenese.
6. They may reveal what indications they chose for Tyrosinase and collagenase
7. Samcyprone results may come in 2015
8. Any other potential catalyst as well
I hope its .88 cents per share that would make for a killer short squeeze but we shall see in the morning.
Me too at least around there. But brand new S-1 filing just now
http://investors.rxipharma.com/Cache/c29736727.html
For some reason they are adding an additional 20% to the original share filing. But they don't need this money right away unless they are
A.) Buying a complimentary business
B.) avoiding a hostile takeover
C.) or have more institutions on board willing to buy a lot of shares
Think about it what other reason would they have to add 20% more over the original shares offered?
They enacted the offering though today after hours market. Last week was S-1 filing. Those aren't instant dilution. S-1 means the company has the right to file later down the line. Today after-hours the company announced it enacted the public offering. Tomorrow Thursday we should probably see a price per share.
Article on Celladon and other gene therapy stocks at Seeking Alpha " Celladon's Failure Shouldn't Trickle Down To Other Gene Therapy Biotechs"
http://seekingalpha.com/article/3210746-celladons-failure-shouldnt-trickle-down-to-other-gene-therapy-biotechs
RXi Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference
http://finance.yahoo.com/news/rxi-pharmaceuticals-present-jefferies-2015-110200176.html
This S1-flingis bullish for RXII for a few reasons:
1. This sell of common shares and warrants is going to be sold to institutional investor/investors
2. The matter the sells are being sold is as an over allotment option -- meaning greenshoe option- google greenshoe option. But the jist is that it was created by a company to the SEC to allow additional shares to be bought to keep the share price stabilized while dilution is taking place. That means price can't go below or above offering price during that time period its enacted.
3. This builds a base around .51 cents per share, and then the insitution/institutions will own between 5% to 10% stake in RXII
4. The investor buying will build investor interest from others on wall street
5. Right now we don't know which institution or institutions is buying 10% of RXII shares. But if its a well known entity expect additional share price appreciation based off of an SEC filing.
It doesn't look like Tang sold any shares today but Tang may decide to keep the rest of his shares. He has 1.5 mil RXII common shares left or 7.44% shares. It's possible Tang may now keep the rest and not sell the remaining but there's no sure way of knowing.
It was a good sign that it doesn't seem like Tang dumped any shares today though.
The huge spike in short interest probably came because of Tang dumping preferred shares to common and then selling them making it easy for short sellers to profit on the way down.